3D Medicines focuses on next-generation immuno-oncology

HELP PEOPLE WITH CANCER

LIVE LONGER AND BETTER

PROVIDE CANCER PATIENTS WITH

PROLONGED SURVIVAL TIME AND A BETTER QUALITY OF LIFE

LEADER IN HELPING CHRONIC CANCER PATIENTS

Company Introduction

3D Medicines, Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.

January 2026

March 2020

October 2020

November 2020

December 2020

January 2021

March 2021

April 2021

December 2022

August 2023

March 2024

February 2025

March 2025

August 2025

January 2026

PipelineThe company has established a multi-core collaborative clinical pipeline

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

Candidate
Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase Ⅱ

Phase Ⅲ

NDA

Partner

Envafolimab

PD-L1

Worldwide

MSI-H/dMMR advanced cancer (mono, 2L+)
Advanced BTC (combo with chemo vs. chemo, 1L)
NSCLC (Adjuvant/Neo-adjuvant therapy, 1L)
G/GEJ advanced cancer (combo with chemo, 1L)
TMB-H advanced cancer (mono, 2L+)
EC (mono and combo with lenvatinib, 2L+)
HCC, CRC, NSCLC (combo with BD0801)
dMMR advanced solid tumors (mono, 2L+)

3D1015

全球

mCRPC

3D128

hematological malignancies/autoimmune diseases

3D189

Greater China

Multiple indications
AML

3D229

GAS6/AXL

Greater China

Healthy Volunteers

3D1001

COX-2

Post-surgical dental pain/cancer pain

Haihe Biopharma Group

3D1002

EP-4

China

Cancer pain / osteoarthritis

3D185

FGFR1/2/3

Worldwide

Locally advanced or metastatic solid tumors

3D011

TKI prodrug

Worldwide

Advanced malignant solid tumors

3D124

mRNA

全球

Multiple Indications

3D197

CD47

Greater China

Multiple indications

3D057

CD3+PD-L1

Greater China + Worldwide Priority Transfer right

Multiple indications

Y-Biologics

3D059

WT1肿瘤疫苗

Worldwide

Multiple indications

3D062

KRAS

Worldwide

Multiple indications

Envafolimab

Target/Mechanism
PD-L1

Rights
Worldwide

Indication

MSI-H/dMMR advanced cancer (mono, 2L+)

Partner

MORE

MSI-H/dMMR advanced cancer (mono, 2L+)

Advanced BTC (combo with chemo vs. chemo, 1L)

NSCLC (Adjuvant/Neo-adjuvant therapy, 1L)

G/GEJ advanced cancer (combo with chemo, 1L)

TMB-H advanced cancer (mono, 2L+)

EC (mono and combo with lenvatinib, 2L+)

HCC, CRC, NSCLC (combo with BD0801)

dMMR advanced solid tumors (mono, 2L+)

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D1015

Target/Mechanism
RDC

Rights
全球

Indication

mCRPC

Partner

MORE

mCRPC

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D128

Target/Mechanism

Rights

Indication

hematological malignancies/autoimmune diseases

Partner

MORE

hematological malignancies/autoimmune diseases

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D189

Target/Mechanism
WT1

Rights
Greater China

Indication

Multiple indications

Partner

MORE

Multiple indications

AML

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D229

Target/Mechanism
GAS6/AXL

Rights
Greater China

Indication

Healthy Volunteers

Partner

MORE

Healthy Volunteers

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D1001

Target/Mechanism
COX-2

Rights

Indication

Post-surgical dental pain/cancer pain

Partner Haihe Biopharma Group

MORE

Post-surgical dental pain/cancer pain

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D1002

Target/Mechanism
EP-4

Rights
China

Indication

Cancer pain / osteoarthritis

Partner

MORE

Cancer pain / osteoarthritis

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D185

Target/Mechanism
FGFR1/2/3

Rights
Worldwide

Indication

Locally advanced or metastatic solid tumors

Partner

MORE

Locally advanced or metastatic solid tumors

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D011

Target/Mechanism
TKI prodrug

Rights
Worldwide

Indication

Advanced malignant solid tumors

Partner

MORE

Advanced malignant solid tumors

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D124

Target/Mechanism
mRNA

Rights
全球

Indication

Multiple Indications

Partner

MORE

Multiple Indications

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D197

Target/Mechanism
CD47

Rights
Greater China

Indication

Multiple indications

Partner

MORE

Multiple indications

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D057

Target/Mechanism
CD3+PD-L1

Rights
Greater China + Worldwide Priority Transfer right

Indication

Multiple indications

Partner Y-Biologics

MORE

Multiple indications

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D059

Target/Mechanism
WT1肿瘤疫苗

Rights
Worldwide

Indication

Multiple indications

Partner

MORE

Multiple indications

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing
3D062

Target/Mechanism
KRAS

Rights
Worldwide

Indication

Multiple indications

Partner

MORE

Multiple indications

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA Filing

Marketing

CEO MESSAGE

As a young biotechnology company, our goal is to achieve several milestones and make profitable innovation. We are steadfast in strengthening our internal discovery capability and conducting pivotal clinical trials to address unmet medical needs to provide more treatment options for cancer patients.

we are confident that we are well-positioned to achieve our vision of transforming cancer from a terminal illness into a manageable chronic disease. We have a robust pipeline of differentiated cancer therapies that address unmet medical needs in the future and offer significant valuation to patients, physicians, and payers. We have a talented and passionate team of scientists, clinicians and professionals who are committed to delivering on our promise of bringing hope and healing to millions of cancer patients around the world

-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.

News

Six Envafolimab Studies Selected for ESMO 2026, as 3D Medicines Continues to Expand the Boundaries of Subcutaneous Immunotherapy

The 2026 Congress of the European Society for Medical Oncology (ESMO) is being held in Madrid, Spain, from October 23 to 27. As one of the international oncology bellwethers alongside ASCO and WCLC, the studies selected for ESMO represent the most valuable clinical advances of the year.Envafolimab (injection), the world's first approved subcutaneous PD-L1 inhibitor and a commercialized product of 3D Medicines (1244.HK), has six studies featured at this year's congress: one Rapid Oral presentation, four posters and one e-Poster. The studies span biliary tract cancer, MSI-H/dMMR advanced solid tumors, extensive-stage small cell lung cancer, soft tissue sarcoma, locally advanced colon cancer and gallbladder cancer — a China-developed regimen that completes administration in 30 seconds and continues to push the boundaries of subcutaneous immunotherapy.

Among them, the registrational Phase III study ofEnvafolimab plus GEMOX as first-line treatment for advanced biliary tract cancer was selected for a Rapid Oral presentation. The marketing application based on this study was accepted by China's National Medical Products Administration (NMPA) in January 2026, and is expected to offer a new first-line subcutaneous immuno-combination option for patients with advanced biliary tract cancer.

2026-10

27
News

AACR 2026: Keyisheng Pharma, a Subsidiary of 3D Medicines, Unveils First Preclinical and Preliminary Clinical Data of Its In-House RDC Candidate 3D1015

From April 17 to 22, 2026 local time, the 117th Annual Meeting of the American Association for Cancer Research (AACR) was held at the San Diego Convention Center in the United States. Keyisheng Pharma, a controlled subsidiary of 3D Medicines Inc. (Stock Code: 1244.HK) focusing on innovative radiopharmaceutical R&D, unveiled for the first time the preclinical and preliminary clinical data of its independently developed PSMA-targeted radiopharmaceutical drug conjugate (RDC), ¹⁷⁷Lu-PSMA-3D1015 (hereinafter referred to as “3D1015s”).

2026-04

27
News

3D Medicines Appoints Mr. Gan Ding as Chief Commercial Officer

February 8th, 2025, Shanghai, China—3D Medicines Inc. (1244.HK) today announced the appointment of Mr. Gan Ding as Chief Commercial Officer (CCO). With three decades of experience in the biopharmaceutical industry across China, the United States, and internationally, Mr. Ding brings a wealth of expertise that will drive the future commercial development of 3D Medicines.

2025-02

08

Company Introduction

January 2026

PipelineThe company has established a multi-core collaborative clinical pipeline

Pipeline

CEO MESSAGE

Company News

Six Envafolimab Studies Selected for ESMO 2026, as 3D Medicines Continues to Expand the Boundaries of Subcutaneous Immunotherapy

AACR 2026: Keyisheng Pharma, a Subsidiary of 3D Medicines, Unveils First Preclinical and Preliminary Clinical Data of Its In-House RDC Candidate 3D1015

3D Medicines Appoints Mr. Gan Ding as Chief Commercial Officer